Abstract
Background The Warburg effect is a hallmark of cancer and is characterized by increased glucose consumption and lactate formation. Deuterium metabolic imaging (DMI) is an emerging non-invasive MRI method for probing this metabolic reprogramming in the field of neuroimaging. Here we show the feasibility of the technique for abdominal imaging using a routine 3 T MRI system, which has previously presented significant technical challenges.
Purpose This study aimed to translate abdominal DMI to clinical field strength by optimizing the radiofrequency coil setup, the administered dose of deuterium (2H)-labelled glucose, and the data processing pipeline for quantitative characterization of DMI signals over time in the kidney and liver, establishing a basis for routine clinical studies in the future.
Materials and Methods Five healthy volunteers were recruited and imaged on 2 or 3 occasions, with different 2H-glucose doses (totalling 13 DMI scan sessions). DMI was performed at 3 T using a flexible 20 x 30 cm2 2H-tuned transmit-receive surface coil. We have defined three novel quantitative parameters as metrics of metabolism and compared these between doses and organs.
Results The careful positioning of a dedicated surface coil minimized unwanted gastric signals while maintaining excellent hepatic and renal measurements. The timecourses derived from the liver and kidney were reproducible and comparable across different doses, with a trend towards lower quantitative measurements with decreasing dose. An increase in the 2H-water signal over time particularly in the liver, could be used as an indirect measure of metabolism.
Conclusion DMI of the human abdomen is feasible using a routine MRI system and the metabolism measured in the kidney and liver can serve as a reference for future clinical studies. The 2H-glucose dose can be reduced from 0.75 to 0.25 g/kg to minimize gastric signal without substantially affecting the reliability of organ quantification.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
ISRCTN: 13008110
Funding Statement
PW acknowledges support from the Gates Cambridge Trust (#OPP1144). MM acknowledges support from the Cambridge Experimental Cancer Medicine Centre. This research was further supported by Cancer Research UK (CRUK; C19212/A27150; C19212/A29082), CRUK Cambridge Centre, Wellcome Trust, NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. The authors also acknowledge support from the National Cancer Imaging Translational Accelerator (NCITA) and The Mark Foundation Institute for Integrative Cancer Medicine (MFICM) at the University of Cambridge.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee 23/YH/0127 of Yorkshire & The Humber of Leeds East Research Ethics Committee gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Figure 3 was updated, as the previous version contained an error.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
